A percutaneous absorption formulation comprising: (a) a drug-containing adhesive layer which contains melatonin or a pharmaceutically acceptable salt thereof as an active ingredient, a solubilizing agent, a crystallization inhibitor, a percutaneous absorption enhancer, an antioxidant, and a polymeric adhesive agent; (b) a support layer; and (c) a release layer, wherein the drug-containing adhesive layer contains, based on the total weight of the drug-containing adhesive layer, 3.0 to 20 wt% of melatonin or the pharmaceutically acceptable salt thereof, 1 to 30 wt% of the solubilizing agent, 0.05 to 5 wt% of the crystallization inhibitor, 1 to 30 wt% of the percutaneous absorption enhancer, 0.1 to 5 wt% of the antioxidant, and 50 to 94.85 wt% of the polymeric adhesive agent, wherein the solubilizing agent is one or two or more selected from the group consisting of N-methylpyrrolidone, dipropylene glycol, propylene glycol, propylene carbonate, ethoxydiglycol, diethylene glycol monoethyl ether, triacetin, triethyl citrate, triethanolamine, tromethamine, bis-Tris, aminomethyl propanediol, aminoethyl propanediol, and polyoxyethylene sorbitan monooleate, wherein the crystallization inhibitor for inhibiting crystal formation of the drug is polyvinylpyrrolidone and/or an amino acrylic methacrylate copolymer, wherein the percutaneous absorption enhancer is a C8-18 aliphatic derivative, wherein the C8-18 aliphatic derivative is one or two or more selected from the group consisting of glycerol lauryl alcohol, oleyl alcohol, isopropyl myristate, sorbitan monooleate, propylene glycol monolaurate, propylene glycol monooleate, oleoyl macrogolglycerides, oleic acid, lauroyl macrogol glyceride, linoleoyl macrogol glyceride, propylene glycol dicaprylate/caprate, sorbitan monostearate, glycerol monooleate, glycerol monolaurate, sorbitan monolaurate, lauryl lactate, PEG-8 caprylic/capric triglycerides, polyoxyethylene sorbitan monolaurate, corn oil PEG-8 esters, and corn oil PEG-6 esters, and wherein the antioxidant is one or two or more selected from the group consisting of butyl hydroxy toluene, butyl hydroxy anisole, propyl galate, ascorbic acid, tocopherol, tocopherol acetate, and ascorbyl palmitate. wherein the drug-containing adhesive layer contains, based on the total weight of the drug-containing adhesive layer, 3.0 to 20 wt% of melatonin or the pharmaceutically acceptable salt thereof, 1 to 30 wt% of the solubilizing agent, 0.05 to 5 wt% of the crystallization inhibitor, 1 to 30 wt% of the percutaneous absorption enhancer, 0.1 to 5 wt% of the antioxidant, and 50 to 94.85 wt% of the polymeric adhesive agent, wherein the solubilizing agent is one or two or more selected from the group consisting of N-methylpyrrolidone, dipropylene glycol, propylene glycol, propylene carbonate, ethoxydiglycol, diethylene glycol monoethyl ether, triacetin, triethyl citrate, triethanolamine, tromethamine, bis-Tris, aminomethyl propanediol, aminoethyl propanediol, and polyoxyethylene sorbitan monooleate, wherein the crystallization inhibitor for inhibiting crystal formation of the drug is polyvinylpyrrolidone and/or an amino acrylic methacrylate copolymer, wherein the percutaneous absorption enhancer is a C8-18 aliphatic derivative, wherein the C8-18 aliphatic derivative is one or two or more selected from the group consisting of glycerol lauryl alcohol, oleyl alcohol, isopropyl myristate, sorbitan monooleate, propylene glycol monolaurate, propylene glycol monooleate, oleoyl macrogolglycerides, oleic acid, lauroyl macrogol glyceride, linoleoyl macrogol glyceride, propylene glycol dicaprylate/caprate, sorbitan monostearate, glycerol monooleate, glycerol monolaurate, sorbitan monolaurate, lauryl lactate, PEG-8 caprylic/capric triglycerides, polyoxyethylene sorbitan monolaurate, corn oil PEG-8 esters, and corn oil PEG-6 esters, and wherein the antioxidant is one or two or more selected from the group consisting of butyl hydroxy toluene, butyl hydroxy anisole, propyl galate, ascorbic acid, tocopherol, tocopherol acetate, and ascorbyl palmitate.